Meeting
2023 ASCO Annual Meeting
Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.
Authors
Mavis Obeng-Kusi
The University of Arizona, Tucson, AZ
Mavis Obeng-Kusi , Denise Roe , Brian L Erstad , Ivo Abraham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3605)
DOI
10.1200/JCO.2023.41.16_suppl.3605
Abstract #
3605
Poster Bd #
305
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Quality Care Symposium
Comparative effectiveness of antiangiogenesis inhibitors for second-line therapy of metastatic colorectal cancer.
First Author: Christina Xiaoyue Chen
Poster
2021 ASCO Annual Meeting
Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Marwan Fakih
Poster
2019 ASCO Annual Meeting
A cost-utility analysis of atezolizumab in the second-line treatment of metastatic urothelial carcinoma.
First Author: Ambika Parmar
Poster
2017 Gastrointestinal Cancers Symposium
Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis.
First Author: Gong Chen